Clinical trials: Chronic Heart Failure and Reduced Ejection Fraction (HFrEF)
Heart Failure With Reduced Ejection Fraction, HFrEF
VisONE Heart Failure Study: Pilot
The VisONE HF pilot is a feasibility pilot for evaluating the benefits and risks of chronically delivering Asymptomatic Diaphragmatic Stimulation in medical refractory heart failure patients using the VisONE™ implantable system…
- Trial name
- NCT03484780
- Testing
- VisONE ADS
- Where
- 3 sites in Georgia, Ukraine
- Volunteers
- 15 people
- Sponsor
- VisCardia Inc.
Heart Failure
REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction
This study is researching an experimental drug called REGN5381 (called "study drug"). The study is focused on patients with heart failure with reduced ejection fraction (ie, the heart is not functioning as well as it should).
- Trial name
- NATRIX-BNP (NCT06237309)
- Testing
- REGN5381
- Where
- 44 sites in United States, Belgium and 10 more
- Volunteers
- 89 people
- Sponsor
- Regeneron Pharmaceuticals
Chronic Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF)
Precision Subtyping and Prognostic Study of Heart Failure Based on Multi-Omics Integration and Clinical Indicators: A Prospective Single-Center Cohort Study
This is a prospective single-center cohort study conducted at The First Affiliated Hospital of Xinjiang Medical University, aiming to enroll 400 patients with chronic heart failure (including HFrEF, HFmrEF, HFpEF) and 200 healthy…
- Conditions
- Chronic Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF), Heart Failure With Preserved Ejection Fraction (HFPEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
- Trial name
- HF-MultiOmics (NCT07355088)
- Where
- China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Xinjiang Medical University
Type 2 Diabetes, Heart Failure, Reduced Ejection Fraction
Acute and Chronic Effects of Oral Ketones in Subjects With HFrEF and Diabetes
This study will provide insight into whether cardiac function changes with oral Ketone Esters (KE) administered to patients with Type 2 Diabetes Mellitus (T2DM) and Heart failure with reduced ejection fraction (HFrEF).
- Trial name
- NCT06108076
- Testing
- Ketone Monoester (KE)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Chronic Heart Failure With Reduced Ejection Fraction
An Observational Study, Called VERI-China, to Learn More About How Well Vericiguat Works and How Safe it is in Real-world Setting in People With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) in China
This is an observational study in which data from people in China with chronic heart failure with reduced ejection fraction (HFrEF) who will be receiving vericiguat treatment are collected.
- Trial name
- VERI-China (NCT05728502)
- Testing
- Vericiguat (Verquvo, BAY1021189), Standard of Care (SoC)
- Where
- China
- Volunteers
- 2,400 people
- Sponsor
- Bayer
Heart Failure With Reduced Ejection Fraction (HFrEF)
A Study to Evaluate the Safety and Efficacy of AC01 Compared to Placebo in Participants With Chronic Heart Failure
The primary purpose of the study is to evaluate the safety and efficacy of 2 doses of AC01 compared to placebo over 12 weeks in participants with chronic advanced HFrEF.
- Trial name
- GOAL-HF2 (NCT07584967)
- Testing
- AC01
- Volunteers
- 400 people
- Sponsor
- AnaCardio AB
Chronic Heart Failure With Reduced Ejection Fraction
A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)
The purpose of this study is to evaluate the efficacy and safety of vericiguat in participants with chronic heart failure with reduced ejection fraction (HFrEF), specifically those with symptomatic chronic HFrEF who have not had…
- Trial name
- VICTOR (NCT05093933)
- Testing
- Vericiguat
- Where
- 519 sites in United States, Argentina and 34 more
- Volunteers
- 6,106 people
- Sponsor
- Merck Sharp & Dohme LLC
Heart Failure
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-REDUCED)
Objective of the study is to find the optimal dose of the once daily oral soluble guanylate cyclase stimulator (sGC) BAY1021189 for Phase III that can be given in addition to standard therapy for heart failure with reduced…
- Trial name
- NCT01951625
- Testing
- Vericiguat (BAY1021189) (1.25 mg), Vericiguat (BAY1021189) (5 mg)
- Where
- 157 sites in United States, Australia and 22 more
- Volunteers
- 456 people
- Sponsor
- Bayer
Heart Failure
Effect of Pre-Hospital ARNI Therapy on Short-Term Outcomes in HFrEF
This study looks at people with heart failure who are admitted to the hospital. The goal of the study is to understand whether taking a heart failure medicine called angiotensin receptor-neprilysin inhibitor (ARNI) before…
- Trial name
- NCT07347925
- Testing
- Prehospital ARNI use, No prehospital ARNI use
- Where
- Egypt
- Volunteers
- 140 people
- Sponsor
- Future University in Egypt
Chronic Heart Failure, Cardiovascular Diseases
AI-Based Monitoring System for Chronic Heart Failure With Advanced Wearable and Mini-Invasive Devices
The goal of this observational, multicenter study is to evaluate whether AI-driven remote monitoring using a mini-invasive wearable device can improve clinical outcomes in adult patients (≥18 years) with chronic heart failure…
- Conditions
- Chronic Heart Failure, Cardiovascular Diseases, Heart Failure With Reduced Ejection Fraction (HFrEF), Heart Failure With Preserved Ejection Fraction (HFPEF)
- Trial name
- SMART-CARE (NCT06909682)
- Testing
- Intervention Group (Device Group - AI-Based Remote Monitoring), Standard Clinical Follow-Up
- Where
- Italy
- Volunteers
- 205 people
- Sponsor
- University of Salerno
Chronic Heart Failure
Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction
This study will evaluate the efficacy, safety, tolerability and pharmacokinetics of JTT-861 administered once daily for 12 weeks in subjects with heart failure with reduced ejection fraction (HFrEF) who are on a stable…
- Trial name
- POWER-HF (NCT06017609)
- Testing
- JTT-861 Capsules
- Where
- 75 sites in United States, Bulgaria and 4 more
- Volunteers
- 314 people
- Sponsor
- Akros Pharma Inc.
Chronic Heart Failure and Reduced Ejection Fraction (HFrEF)
Secondary Use of PARALLEL-HF Data
This study utilized the blood and first morning void (FMV) urine samples from the PARALLEL-HF study (core part). The PARALLEL-HF study (core part) was a multicenter, randomized, double-blind, double-dummy, parallel-group…
- Trial name
- NCT07527767
- Where
- Japan
- Volunteers
- 236 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Heart Failure With Reduced Ejection Fraction
A Study to Learn How Safe Starting Vericiguat at a Dose of 5 Milligrams is in Participants With Chronic Heart Failure With Reduced Ejection Fraction
Researchers are looking for a better way to treat people who have chronic heart failure with reduced ejection fraction. Chronic heart failure with reduced ejection fraction (HFrEF) is a long-term condition that occurs when the…
- Trial name
- NCT06195930
- Testing
- Vericiguat (BAY1021189) 5 mg
- Where
- 35 sites in United States, Argentina and 5 more
- Volunteers
- 106 people
- Sponsor
- Bayer
Chronic Kidney Disease, Heart Failure With Reduced Ejection Fraction (HFrEF)
Single and Twice-daily Dosing of Ramipril on Renal Function in Chronic Kidney Disease Patients With Reduced Ejection Fraction Heart Failure
This study compares the effects of once-daily versus twice-daily ramipril dosing on renal function in chronic kidney disease (CKD) patients with heart failure with reduced ejection fraction (HFrEF).
- Trial name
- NCT07259512
- Testing
- Ramipril
- Where
- Indonesia
- Volunteers
- 80 people
- Sponsor
- Evi Liliek Wulandari
Cardiorenal Syndrome
Exercise Rehabilitation for Cardiorenal Syndrome in HFrEF Patients
This study aims to investigate the efficacy and safety of exercise rehabilitation in patients with cardiorenal syndrome (CRS). Building on previous research demonstrating that exercise rehabilitation can effectively improve…
- Trial name
- NCT07167368
- Testing
- Standardized Basic Drug Therapy for HFrEF with Chronic Kidney Dysfunction, Home-based Personalized Exercise Rehabilitation
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Haiyan Pan
Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
Study of JK07 in Patients With Chronic Heart Failure
This is a Phase 2, randomized, double-blind, placebo-controlled, multiple dose study to assess the safety, tolerability, and efficacy of JK07 in participants aged 18-85 with heart failure.
- Trial name
- RENEU-HF (NCT06369298)
- Testing
- JK07
- Where
- 62 sites in United States, Canada and 2 more
- Volunteers
- 282 people
- Sponsor
- Salubris Biotherapeutics Inc
Heart Failure With Reduced Ejection Fraction, Chronic Heart Failure
Vericiguat and Exercise Hemodynamics in Patients With HFrEF
Heart failure with reduced ejection fraction (HFrEF) is associated with impaired exercise capacity and abnormal exercise hemodynamics despite contemporary guideline-directed medical therapy (GDMT).
- Trial name
- EVERHETT-HF (NCT07697365)
- Testing
- Vericiguat, Guideline-directed medical therapy (GDMT) for heart failure
- Where
- Greece
- Volunteers
- 40 people
- Sponsor
- Argyrios Ntalianis
Acute Myocardial Infarction (AMI), Percutaneous Coronary Intervention (PCI)
BRIDGE Trial: Embedding Consumer-grade mHealth Technologies Into Cardiac Rehabilitation
The purpose of the BRIDGE study is to learn whether supplementing traditional center-based cardiac rehabilitation (CBCR) with a mobile health technology intervention can help patients monitor their health, stay engaged in healthy…
- Conditions
- Acute Myocardial Infarction (AMI), Percutaneous Coronary Intervention (PCI), Coronary Artery Bypass Graft Surgery (CABG), Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)
- Trial name
- BRIDGE (NCT07741396)
- Testing
- CBCR, BRIDGE mHealth intervention
- Volunteers
- 30 people
- Sponsor
- University of Illinois Chicago
Chronic Heart Failure With Reduced Ejection Fraction
Effects of Repletion of Sodium Chloride on Natriuresis, Blood Pressure, and Neurohormonal Activity in Patients With Chronic Heart Failure With Reduced Ejection Fraction
The study is a single-center, prospective, randomized, placebo-controlled, double-blind trial conducted at the Institute of Heart Diseases and the Department of Cardiology of Wroclaw Medical University Hospital.
- Trial name
- RESALT-CHF (NCT07614295)
- Testing
- Sodium chloride supplementation
- Where
- Poland
- Volunteers
- 30 people
- Sponsor
- Wroclaw Medical University
Chronic Total Occlusion Vessel
Benefits of CTO-PCI in Selected Cases With HFrEF (CTOHFrEF)
The investigators studied the effect of CTO-PCI on left ventricular function and clinical parameters in patients with HFrEF.
- Trial name
- CTOHFrEF (NCT02570087)
- Testing
- chronic total coronary occlusion percutaneous intervention
- Volunteers
- 39 people
- Sponsor
- Hospital Clinic of Barcelona